Analysts expect over 2018 rising revenue Biogen

Tomorrow the American Biogen will publish its past quarter's figures. For this year Biogen 's revenue will be around 12,05 billion USD. This is according to the average of the analysts' estimates. This is slightly more than 2016's revenue of 11,45 billion USD.

Historical revenues and results Biogen plus estimates 2018

The analysts expect for 2018 a net profit of 4,68 billion USD. According to most of the analysts the company will have a profit per share for this book year of 21,97 USD. The price/earnings-ratio therefore equals 15,78.

For this year analysts don't expect the company to pay a dividend.The average dividend yield of the biotech companies equals a low 0,06 percent.

Latest estimates around 354 USD

The latest 3 recommendations for the biotech company were provided by Canacord Adams, Credit Suisse and Leerink Swann & Company.

Biogen 's market capitalization is based on the number of outstanding shares around 75,8 billion USD.

On Monday the stock closed at 346,75 USD.

Historical stock prices Biogen2007-2018

ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
news@valuespectrum.com

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.